Table 3.

Targets for immunotherapy in pediatric brain tumors.

Entity	Targets	Therapy Approach	Study
GBM, MB, EPN	EGFRvIII	CAR T cells	[112]
MB, EPN	IL13Rα2	CAR T cells	[109,113]
MB, EPN	HER2	CAR T cells	[109,114,115]
MB, EPN	EPHA2	CAR T cells	[109]
SHH-MB	CD1d	Vα24-invariant (type-I) NKT cells	[116]
MB	PRAME	CAR T cells (SLL TCR T cells with inducible caspase-9 gene)	[117]
MB	No target	allogeneic cord blood-derived NK cells expressing a dominant negative TGF-β receptor	[118]
SHH-MB	CSF1R	CSF1R inhibitor (PLX5622) for TAM depletion	[119]
ATRT, MB, ETMR, EPN, HGG	B7-H3	CAR T cells	[106,107,108]
ATRT, MB, ETMR, EPN, HGG	GD2	CAR T cells	[106,120]
Gr.3-MB, ATRT, PNET, GBM, DMG	CD47	α-CD47 against tumor cells	[111]
ATRT	PD-1	α-PD-1 against PD-1+ immune cells	[15]